[go: up one dir, main page]

WO2000053160A1 - Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs - Google Patents

Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs Download PDF

Info

Publication number
WO2000053160A1
WO2000053160A1 PCT/GB2000/000847 GB0000847W WO0053160A1 WO 2000053160 A1 WO2000053160 A1 WO 2000053160A1 GB 0000847 W GB0000847 W GB 0000847W WO 0053160 A1 WO0053160 A1 WO 0053160A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
active agent
poly
release
microns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/000847
Other languages
English (en)
Inventor
Stephen Joseph Prestrelski
Terry Lee Burkoth
Gordon M. Saul
Kevin John Brodbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Research Ltd
Original Assignee
Powderject Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Research Ltd filed Critical Powderject Research Ltd
Priority to AU29312/00A priority Critical patent/AU770235B2/en
Priority to CA002364198A priority patent/CA2364198A1/fr
Priority to NZ513981A priority patent/NZ513981A/xx
Priority to JP2000603649A priority patent/JP2002538195A/ja
Priority to EP00907848A priority patent/EP1158961A1/fr
Publication of WO2000053160A1 publication Critical patent/WO2000053160A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • the present invention relates to methods of delivering sustained-release particles containing biological agents into organisms.
  • dermal delivery provides a safe, convenient and noninvasive alternative to traditional drug administration systems, conveniently avoiding the major problems associated with oral delivery (e.g., variable rates of absorption and metabolism, food effects, gastrointestinal irritation and/or bitter or unpleasant drug tastes, and inability to deliver large molecules) or other types of parenteral delivery (e.g., needle pain, the risk of introducing infection to treated individuals, the risk of contamination or infection of health care workers caused by accidental needle-sticks and the disposal of used needles).
  • dermal delivery affords a degree of control over blood concentrations of administered pharmaceuticals.
  • dermal delivery presents a number of its own inherent logistical problems.
  • the passive delivery of drugs through intact skin necessarily entails the transport of molecules through a number of structurally different tissues, including the stratum corneum, the viable epidermis, the papillary dermis, and the capillary walls in order for the drug to gain entry into the blood or lymph system.
  • Transdermal delivery systems must therefore be able to overcome the various resistances presented by each type of tissue.
  • U.S. Patent No. 5,630,796 to Bellhouse et al (which is incorporated herein by reference in its entirety) describes a needleless syringe that delivers pharmaceutical particles entrained in a supersonic gas flow.
  • the needleless syringe is used for dermal delivery of drug compounds and compositions, for delivery of genetic material into living cells (e.g. , gene therapy) and for the delivery of biopharmaceuticals to skin, muscle, blood or lymph.
  • the needleless syringe can also be used in conjunction with surgery to deliver drugs and biologies to organ surfaces, solid tumors and/or to surgical cavities (e.g., tumor beds or cavities after tumor resection).
  • the particles of drug delivered by the syringe are sufficiently small that they do not cause tissue distension sufficient to trigger the pain receptors in the skin.
  • the syringe eliminates the chance of infection from accidental needlestick injury or splash back of bodily fluids, avoiding the possibility of cross- contamination with blood borne pathogens such as HIN and hepatitis B.
  • the dry powder compositions used in the syringe are more stable and therefore less expensive to store and distribute and do not require refrigeration or reconstitution before delivery.
  • the needleless injection technology can be applied to the delivery of biologically active materials to a wide range of organisms ranging from cells to whole animals to man where the biologically active material effects a change within the organism.
  • the bioactive ingredient used for syringe delivery has been formulated to be readily or instantly available upon delivery to the organism.
  • sustained-release technology In the field of human and veterinary medicine many advantages are offered by sustained-release technology. First, sustained-release of a pharmaceutical agent allows less frequent dosing and thus minimizes handling of animals and repeated treatment of humans. Further, sustained-release treatment results in more efficient drug utilization. Further, less of the compound remains as a residue. Still further, sustained-release technology offers the opportunity to administer and release two or more different drugs, each having a unique release profile, or to release the same drug at different rates or for different durations, by means of a single dosage unit.
  • compositions suitable for administration to a subject by means of a needleless syringe which composition comprises particles which have a mean mass aerodynamic diameter of from 1 to 250 microns and an envelope density of from 0.1 to 25 g/cm 3 , the particles comprising a biologically active agent and a sustained-release material which controls the release of the active agent to the subject following administration.
  • compositions wherein the mean mass aerodynamic diameter of the particles is from about 10 to 100 microns, less than 10% by weight of the particles have a diameter which is 5 microns more or 5 microns less than the mean mass aerodynamic diameter, the envelope density of the particles is from 0.8 to 1.5 g/cm 3 , the particles exhibit less than 25% reduction in mass mean diameter in a particle attrition test and the particles have an axis ratio of from 3:1 to 1: 1.
  • Such compositions are especially able to withstand the forces associated with high velocity particle injection techniques.
  • the invention also provides: a hermetically sealed single unit dosage or multidose container adapted for use in a needleless syringe, the said container comprising a composition according to the invention; - a needleless syringe loaded with a composition of the invention; use of a biologically active agent in the manufacture of a paniculate medicament for administration to a subject by means of a needleless syringe, the particles of the medicament having a mean mass aerodynamic diameter of from 0.1 to 250 microns and an envelope density of from 0.1 to 25 g/cm 3 and also comprising a sustained- release material which controls the release of the active agent to the subject following administration of the medicament thereto; and a method for delivering a biologically active agent to an organism, comprising: (a) providing particles which have a mean mass aerodynamic diameter of from 0.1 to 250 microns and an envelope density of from 0.1 to 25 g/cm 3 and which comprise a biologically active agent and a sustained-release material which controls the release of the active agent to the
  • the present invention is concerned with delivering a biologically active agent to an organism by particle injection.
  • the particles comprise a biologically active agent and sustained-release material which controls the release of the active agent to the organism following injection.
  • the particles have a mean mass aerodynamic diameter (MMAD) of from about 0.1 to 250 microns and an envelope density of from 0.1 to 25 g/cm 3 .
  • MMAD mean mass aerodynamic diameter
  • the particles have sufficient structural integrity to withstand being fired from a needleless syringe and impacting skin or mucosal tissue at high velocity, typically a supersonic velocity of from Mach 1 to Mach 8.
  • the particles are typically microcapsules which have encapsulated material, hereinafter referred to as a "biologically active agent", centrally located within a unique membrane, usually a polymeric membrane. This membrane delays or otherwise controls the agent's release.
  • the membrane may be termed a wall-forming material. Because of their internal structure, permeable microcapsules designed for sustained-release applications can be made which release their agent at a substantially constant rate (zero-order rate of release). Also, impermeable microcapsules can be used for rupture-release applications. Alternatively, the particles may take the form of microspheres.
  • a microsphere can have the active agent dispersed throughout the particle; that is, the internal structure is a matrix of the active agent and excipient, usually a polymeric excipient known as a "sustained-release material" which affects the release rate.
  • sustained-release microspheres release their agent at a declining rate (first-order).
  • microspheres can be designed to release agents at a near zero-order rate. Microspheres tend to be more difficult to rupture as compared to microcapsules because their internal structure is stronger. This can be advantageous in view of the rigorous delivery conditions presented by needleless injection.
  • the active material is released from the microparticles by diffusion, leaching or erosion of the matrix (eg. biodegradation) or by a combination of these mechanisms.
  • microparticle is synonymous with and includes the terms “microsphere” and "microcapsule” .
  • the microparticle composition is substantially dry or powder-like, i.e. liquid has not been added to the composition. Some minor amounts of liquid may however remain with the microparticles.
  • the polymeric matrix material of the microparticles present invention can be composed of a biocompatible and biodegradable polymeric material.
  • biocompatible material is defined as a polymeric material which is not toxic to an animal and not carcinogenic.
  • the matrix material is preferably biodegradable in the sense that the polymeric material should degrade by bodily processes in vivo to products readily disposable by the body and should not accumulate in the body.
  • the matrix material need not be biodegradable.
  • the microparticles of the present invention usually have a spherical shape, although irregularly-shaped microparticles are possible. When viewed under a microscope, therefore, the particles are typically spheroidal but may be elliptical, irregular in shape or toroidal.
  • the microparticles vary in size, ranging in diameter from 0.1 microns to 250 microns, more preferably, from 10 or 20 microns to 75 microns and most preferably from 30 microns to 70 microns.
  • sustained-release as used herein encompasses the term
  • controlled-release and means that the biologically active agent is released from the microparticle polymeric matrix over an extended period of time so as to give continuing or delayed dosage of the treated organism.
  • the controlled-release period can be from a few hours to 1 to 500 days or longer and preferably is from 3 to 60 days.
  • the duration of release of the active agent from the microparticle can be adjusted from less than a week to several months or longer by manipulation of various parameters.
  • the amount (level) of biologically active agent released can also be controlled.
  • the parameters include the polymer composition of the controlled- release material, the polymer molecular weight, the polymer :bioactive agent ratio, microparticle diameter and the presence/absence of a release rate modifier in the composition.
  • Other parameters include bound/unbound drug (with respect to a polymer matrix), hydrophobicity of the drug and/or polymer composition and porosity of the polymer matrix. Mixed populations of different types of microparticles can be combined into single dosage forms and can be co-administered.
  • the same active agent can be incorporated into the different microparticle types that are combined in the final formulation or co-administered. Thus, multiphasic delivery of the same active agent can be achieved.
  • two or more active agents can be combined in the microparticle composition.
  • the additional bioactive agent(s) can be unencapsulated, encapsulated separately, or co-encapsulated with the first active agent. If separately encapsulated, the matrix may be the same or different for each agent at predetermined release rates with the release of each drug being at a different rate and duration by design. As above, any of the parameters may be varied to produce unique microparticles having specific release characteristics for the given encapsulated agent.
  • administer or “deliver” is intended to refer to any delivery method using needleless syringes or the like means of accelerating the microparticle composition onto the tissue or skin or wall of the organism thereby causing the microparticles to penetrate the surface and become available to the organism.
  • administration may be either for prophylactic or therapeutic purpose.
  • the bioactive agent is provided in advance of any symptom. The prophylactic administration of the bioactive agent serves to prevent or attenuate any subsequent symptom.
  • the bioactive agent When provided therapeutically the bioactive agent is provided at (or shortly after) the onset of a symptom.
  • the therapeutic administration of the bioactive agent serves to attenuate any actual symptom.
  • the terms “needleless syringe,” and “needleless syringe device,” as used herein, expressly refer to a particle delivery system that can be used to deliver the microparticles into and/or across tissue.
  • the particles have an average size ranging from about 0.1 to 250 microns. Particles larger than about 250 microns can also be delivered from these devices, with the upper limitation being the point at which the size of the particles would cause untoward pain and/or damage to the target tissue.
  • the microparticles are delivered by the needleless syringe at high velocity, preferably at velocities of at least about 100 meters/second or greater, more preferably at velocities of about 250 meters/second or greater and most preferably at velocities of at least about 300 meters/second or greater.
  • Such needleless syringe devices are described in U.S. Patent No. 5,630,796 to Bellhouse et al, incorporated herein by reference in its entirety, and have since been described in International Publication Nos. WO 96/04947, WO 96/12513, and WO 96/20022, all of which publications are also incorporated herein by reference in their entirety. Since the term only relates to devices which are suitable for delivery of paniculate materials, devices such as liquid-jet injectors are expressly excluded from the definition of a "needleless syringe.”
  • organism refers to eukaryotic cells whether in vivo or in vitro, eukaryotic tissues whether in vivo or in vitro, and animals, individuals, patients and subjects as defined herein.
  • animal refers to a subset of organisms which include any member of the subphylum cordata, including, without limitation, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as bovine animals, for example cattle; ovine animals, for example sheep; porcine, for example pigs; rabbit, goats and horses; domestic mammals such as dogs and cats; wild animals; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese; and the like.
  • farm animals such as bovine animals, for example cattle; ovine animals, for example sheep; porcine, for example pigs; rabbit, goats and horses; domestic mammals such as dogs and cats; wild animals; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous
  • tissue refers to the soft tissues of an animal, patient, subject etc as defined herein, which term includes, but is not limited to, skin, mucosal tissue (eg. buccal, conjunctival, gums), vaginal and the like. Bone may however be treated too by the particles of the invention, for example bone fractures.
  • the methods of this invention include treating a disease state in an animal by administering the microparticle composition described herein by a needleless syringe to a subject in need of such treatment.
  • treatment or “treating” includes any of the following: the prevention of infection or reinfection; the reduction or elimination of symptoms; and the reduction or complete elimination of a pathogen. Treatment may be effected prophylactically (prior to infection) or therapeutically (following infection).
  • the methods of this invention also include effecting a change in an organism by administering the microparticle compositions.
  • a "therapeutically effective amount” is defined very broadly as that amount needed to give the desired biologic or pharmacologic effect.
  • agent administered in milligram amounts.
  • sustained-release material includes both wall-forming materials for use in microcapsules and polymeric materials for use in microspheres.
  • the sustained-release material should be biologically acceptable.
  • a "biologically acceptable” material is one which can be present in a biological environment without causing unwanted deleterious effects.
  • Suitable wall-forming materials for use in microcapsules include, but are not limited to, poly(dienes) such as poly(butadiene) and the like; poly(alkenes) such as polyethylene, polypropylene, and the like; poly(acrylics) such as poly(acrylic acid) and the like; poly(methacrylics) such as poly(methyl methacrylate), poly (hydroxy ethyl methacrylate), and the like; poly(vinyl ethers); poly(vinyl alcohols); poly(vinyl ketones); poly(vinyl halides) such as poly(vinyl chloride) and the like; poly(vinyl nitriles), poly(vinyl esters) such as poly(vinyl acetate) and the like; poly(vinyl pyridines) such as poly(2-vinyl pyridine), poly(5-methyl-2-vinyl pyridine) and the like; poly(styrenes); poly(carbonates); poiy(esters
  • a preferred group of wall-forming materials includes biodegradable polymers such as poly(lactide), poly(glycolide), poly(caprolactone), poly(hydroxybutyrate), and copolymers thereof including but not limited to poly(lactide-co-glycolide), poly(lactide-co-caprolactone) and the like. Again, these polymers may be cross-linked.
  • the copolymers may be block, random or regular copolymers.
  • the molecular weight of the polymeric material can be of some importance.
  • the molecular weight should be high enough so that it forms satisfactory polymer coatings, i.e., the polymer should be a good film former.
  • a satisfactory molecular weight is in the range of 5,000 to 500,000 daltons, more preferably in the range of 10,000 to 500,000 daltons although it can be higher.
  • the biodegradable polymers mentioned above generally have molecular weights of from 30,000 to 50,000 daltons, up to about 120,000 daltons such as from 80,000 to 100,000 daltons. Dextrans may have an upper molecule weight of about 500,000.
  • the molecular weight of a polymer is also important from the point of view that molecular weight influences the biodegradation rate of the polymer.
  • the polymer should remain intact until all of the drug is released from the microparticles and then degrade.
  • the drug can also be released from the microparticles as the polymeric excipient bioerodes.
  • a microparticle formulation can be made such that the resulting microparticles exhibit both diffusional release and biodegradation release properties. This is useful in affording multiphasic release patterns.
  • Bimodal release of active agent can be achieved by providing two types of particles having polymeric matrix materials of different molecular weight.
  • Inclusion of a hydrophobic solvent as an additive to the polymer can prolong and control drug release within a designated therapeutic window.
  • weak solvents with a low affinity for water, such as N-methyl-2-pynolidone or triacetin, can be added to a polymer material such as poly(lactide-co-glycolide) to dissolve partially the matrix and thereby block the pores of the maxtrix from direct diffusion of incoming water.
  • release of the biologically active agent can be governed in the initial stages after injection by the affinity of the solvent employed and water.
  • any biologically acceptable biodegradable matrix polymer may be used in the generation of microspheres.
  • suitable examples of polymeric matrix materials include poly(glycolic acid), poly-d,l-lactic acid, poly-1-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), polycaprolactone, polydioxonene, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polydioxonene, polyanhydrides, polyphosphazines, polyethyleneglycol, poly(hydroxy-butyric acid), poly(orthoesters) and natural polymers including, polyamino acids, albumin, casein, and some waxes, such as, glycerol mono- and distearate, and the like.
  • the polymer may be cross-linked.
  • poly (lactide-co-glycolide) materials may be used in the method of the present invention.
  • poly (d,l-lactic-co-glycolic acid) is commercially available from Arkermes (formerly Medisorb) Technologies International L.P. (Cincinnati, Ohio).
  • a suitable product commercially available from Medisorb is a 50:50 poly (d,l) lactic co-glycolic acid known as MEDISORB.RTM. 5050 DL. This product has a mole percent composition of 50% lactide and 50% glycolide.
  • Other suitable commercially available products are MEDISORB.RTM.
  • poly(d,l-lactic acid) (d,l-PLA).
  • Poly(lactide-co-glycolides) are also commercially available from Boehringer Ingelheim (Germany) under its Resomer mark, e.g., PLGA 50:50 (Resomer RG 502), PLGA 75:25 (Resomer RG 752) and d,l-PLA (Resomer RG 206), and from Birmingham Polymers (Birmingham, Ala.). These copolymers are available in a wide range of molecular weights and ratios of lactic acid to glycolic acid.
  • a prefened polymer for use in the practice of this invention is poly(d,l-lactide-co-glycolide). It is preferred that the molar ratio of lactide to glycolide in such a copolymer be in the range of from about 95:5 to about 50:50.
  • the molecular weight of the polymeric material can be of some importance.
  • the molecular weight should be high enough so that it forms satisfactory polymer coatings, i.e., the polymer should be a good film former.
  • a satisfactory molecular weight is in the range of 20,000 to 2,000,000 daltons with, in some instances, physical cross-linking, more preferably in the range of 10,000 to 500,000 daltons although it can be higher.
  • the biodegradable polymers mentioned above generally have molecular weights of from 50,000 to 50,000 daltons, up to about 120,000 daltons such as from 80,000 to 100,000 daltons. Dextrans may have an upper molecule weight of about 2,000,000 to 3,000,000.
  • the molecular weight of a polymer is also important from the point of view that molecular weight influences the biodegradation rate of the polymer.
  • the polymer should remain intact until all of the drug is released from the microparticles and then degrade.
  • the drug can also be released from the microparticles as the polymeric excipient bioerodes.
  • a microparticle formulation can be made such that the resulting microparticles exhibit both diffusional release and biodegradation release properties. This is useful in affording multiphasic release patterns.
  • Bimodal release of active agent can be achieved by providing two types of particles having polymeric matrix materials of different molecular weight.
  • Inclusion of a hydrophobic solvent as an additive to the polymer matrix can prolong and control drug release within a designated therapeutic window.
  • weak solvents, with a low affinity for water such as N-methyl-2-pynolidone or triacetin, can be added to a polymer matrix such as poly(lactide-co-glycolide) to dissolve partially the matrix and thereby block the pores of the maxtrix from direct diffusion of incoming water.
  • release of the biologically active agent can be governed in the initial stages after injection by the affinity of the solvent employed and water.
  • the microsphere includes an inert particle core.
  • the inert particle core includes, but is not limited to, metals such as gold, tungsten, or platinum, metal compounds such as ferrite, and organic polymers such as polystyrene or latex. Such core material are well known in the art.
  • the microparticle will not comprise an inert particle core.
  • a “penetration enhancer” or “permeation enhancer” as used herein is a material which increases the permeability of skin or other material to a biologically active agent remaining or present on the surface of the skin, e.g., so as to increase the rate at which the drug permeates through the skin and enters the bloodstream.
  • the enhanced permeation effected through the use of such enhancers can be observed by measuring the rate of diffusion of drug through animal or human skin using a diffusion cell apparatus well known in the art.
  • Penetration enhancers may be used to facilitate transport of any residual biologically active agent left on the skin at the delivery site by the methods of this invention.
  • An "effective" amount of a permeation enhancer as used herein means an amount that will provide the desired increase in amount of drug delivered by the method of this invention.
  • a "biologically-active agent” includes any compound or composition of matter which, when administered to an organism induces a desired pharmacologic and/or physiologic effect by local and/or systemic action.
  • the term therefore encompasses those compounds or chemicals traditionally regarded as drugs, biopharmaceuticals (including molecules such as peptides, proteins, nucleic acids), vaccines and gene therapies (e.g., gene constructs).
  • Biologically-active agents useful in the composition of this invention include drugs acting at synaptic and neuroeffector junctional sites (cholinergic agonists, anticholinesterase agents, atropine, scopolamine, and related antimuscarinic drugs, catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists); drugs acting on the central nervous systems; drugs affecting renal function and electrolyte metabolism; cardiovascular drugs; drugs affecting gastrointestinal function; chemotherapy of neoplastic diseases; drugs acting on the blood and the blood-forming organs; and hormones and hormone antagonists.
  • drugs acting at synaptic and neuroeffector junctional sites include drugs acting at synaptic and neuroeffector junctional sites (cholinergic agonists, anticholinesterase agents, atropine, scopolamine, and related antimuscarinic drugs, catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists); drugs acting on the central nervous systems; drugs affecting renal function and electrolyte metabolism; cardiovascular drugs; drugs affecting
  • the agents useful in the composition include, but are not limited to anti-infectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; local and general anesthetics; anorexics; anti-arthritics; anti-asthmatic agents; anti-convulsants; antidepressants; antihistamines; anti-inflammatory agents; anti-nauseants; anti- migraine agents; anti-neoplasties; anti-pruritics; anti-psychotics; antipyretics; antispasmodics; cardiovascular preparations (including calcium channel blockers, beta-blockers, beta-agonists and anti-arrythmics); anti-hypertensives; diuretics; vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostics; hormones; bone growth stimulants and bone resorption inhibitors; immunosuppressives; muscle relaxants; psychostimulants; sedatives; and tranquilizers.
  • anti-infectives such
  • drugs useful in this invention include angiotensin converting enzyme (ACE) inhibitors, ⁇ -lactam antibiotics and ⁇ -aminobutyric acid (GABA)-like compounds.
  • ACE inhibitors are discussed in Goodman and Gilman. Eighth Edition at pp. 757-762, which is incorporated herein by reference. These include quinapril, ramipril, captopril, benzepril, fosinopril, lisinopril, enalapril, and the like and the respective pharmaceutically acceptable salts thereof.
  • Beta-lactam antibiotics are those characterized generally by the presence of a beta-lactam ring in the structure of the antibiotic substance and are discussed in Goodman and Gilman.
  • GABA-like compounds may also be found in Goodman and Gilman.
  • Other compounds include calcium channel blockers (e.g., verapamil, nifedipine, nicardipine, nimodipine and diltiazem); bronchodilators such as theophylline; appetite suppressants, such as phenylpropanolamine hydrochloride; antitussives, such as dextromethorphan and its hydrobromide, noscapine, carbetapentane citrate, and chlophedianol hydrochloride; antihistamines, such as terfenadine, phenidamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate; decongestants, such as phenylephrine
  • Biologically active agents that can also be incorporated in the microparticles of the present invention include proteins, peptides, and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced) such as LHRH and analogs thereof, somatostatin, calcitonin, parathyroid hormone, growth hormone, growth hormone releasing factor, GnRH (gonadotrophin releasing hormone), angiotensin, FSH, EGF, vasopressin, ACTH, human serum albumin, gamma globulin, interleukins, interferons, colony stimulating factors, tumor necrosis factor and the like; enzymes such as lactase, pancrelipase, succinic acid dehydrogenase, and the like.
  • proteins such as LHRH and analogs thereof, somatostatin, calcitonin, parathyroid hormone, growth hormone, growth hormone releasing factor, GnRH (gonadotrophin releasing hormone), angiotensin, FSH, E
  • antigens include proteins, polypeptides, antigenic protein fragments, oligosaccharides, polysaccharides, and the like.
  • the antigen can be derived from any known virus, bacterium, parasite, plants, protozoans, or fungus, and can be a whole organism or immunogenic parts thereof, e.g., cell wall components.
  • An antigen can also be derived from a tumor.
  • an oligonucleotide or polynucleotide which expresses an antigen is also included in the definition of antigen.
  • Synthetic antigens are also included in the definition of antigen, for example, haptens, polyepitopes, flanking epitopes, and other recombinant or recombinant or synthetically derived antigens (Bergmann et al. (1993) Eur. J. Immunol. 23 :2777- 2781; Bergmann et al. (1996) J. Immunol. 157:3242-3249: Suhrbier, A. (1997) Immunol. And Cell Biol. 75:402-408; Gardner et al.
  • an antigen when associated with a sustained-release material in accordance with the invention, it can be viewed as a "vaccine composition" and as such includes any pharmaceutical composition which contains an antigen and which can be used to prevent or treat a disease or condition in a subject.
  • the term encompasses both subunit vaccines, i.e., vaccine compositions containing antigens which are separate and discrete from a whole organism with which the antigen is associated in nature, as well as compositions containing whole killed, attenuated or inactivated bacteria, viruses, parasites or other microbes.
  • the vaccine can also comprise a cytokine that may further improve the effectiveness of the vaccine.
  • Viral vaccine compositions used herein include, but are not limited to, those containing, or derived from, members of the families Picornaviridae (e.g., polioviruses, etc.); Caliciviridae; Togaviridae (e.g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae; Biraaviridae; Rhabodoviridae (e.g., rabies virus, measels virus, respiratory syncytial virus, etc.); Orthomyxoviridae (e.g., influenza virus types A, B and C, etc.); Bunyaviridae; Arenaviridae; Retroviradae (e.g., HTLV-I; HTLV-II; HIV-1 ; and HIV-2); simian immunodeficiency virus (SIV) among others.
  • Picornaviridae e.g., polioviruses, etc.
  • viral antigens may be derived from a papilloma virus (e.g., HPV); a herpes virus, i.e. herpes simplex 1 and 2; a hepatitis virus, e.g., hepatitis A virus (HAV), hepatitis B virus (HBN), hepatitis C virus (HCV), the delta hepatitis D virus (HDV), hepatitis E virus (HEV) and hepatitis G virus (HGN) and the tick-borne encephalitis viruses; smallpox, parainfluenza, varicella-zoster, cytomeglavirus, Epstein-Ban, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rubella, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever, lymphocytic choriomeningit
  • Bacterial vaccine compositions used herein include, but are not limited to, those containing or derived from organisms that cause diphtheria, cholera, tuberculosis, tetanus, pertussis, meningitis, and other pathogenic states, including Meningococcus A, B and C, Hemophilus influenza type B (HIB), and Helicobacter pylori; Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parain
  • anti-parasitic vaccine compositions include those derived from organisms causing malaria and Lyme disease. Antigens of such fungal, protozoan, and parasitic organisms such as Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis, Schistosoma mansoni, and the like.
  • Antigens of such fungal, protozoan, and parasitic organisms such as Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardi
  • antigens include allergens such as cat dander, birch pollen, house dust mite, grass pollen, and the like.
  • Suitable nucleotide sequences for use in the present invention include any therapeutically relevant nucleic acid molecules (polymeric forms of two or more nucleotides, either ribonucleotides (RNA) or deoxyribonucleotides (DNA)) including double- and single-stranded molecules and supercoiled or condensed molecules, gene constructs, expression vectors, plasmids, antisense molecules and the like.
  • RNA ribonucleotides
  • DNA deoxyribonucleotides
  • the present invention can be used to deliver one or more genes encoding a protein defective or missing from a target cell genome or one or more genes that encode a non-native protein having a desired biological or therapeutic effect (e.g., an antiviral function).
  • the invention can also be used to deliver a nucleotide sequence capable of providing immunity, for example an immunogenic sequence that serves to elicit a humoral and/or cellular response in a subject, or a sequence that corresponds to a molecule having an antisense or ribozyme function.
  • Suitable genes which can be delivered include those used for the treatment of inflammatory diseases, autoimmune, chronic and infectious diseases, including such disorders as AIDS, cancer, neurological diseases, cardiovascular disease, hypercholestemia; various blood disorders including various anemias, thalassemia and hemophilia; genetic defects such as cystic fibrosis, Gaucher's Disease, adenosine deaminase (ADA) deficiency, emphysema, etc.
  • antisense oligonucleotides e.g., short oligonucleotides complementary to sequences around the translational initiation site (AUG codon) of an mRNA
  • a number of antisense oligonucleotides that are useful in antisense therapy for cancer and for viral diseases have been described in the art. See, e.g., Han et al. 1991) Proc. Natl. Acad Sci. USA 8.8:4313; Uhlmann et al. (1990) Chem. Rev. 90:543; Helene et al. (1990) Biochim. Biophys. Ada. 1049:99: Agarwal et al. (1988) Proc. Natl. Acad. Sci.
  • genes encoding toxic peptides i.e., chemotherapeutic agents such as ricin, diphtheria toxin and cobra venom factor
  • tumor suppressor genes such as p53
  • genes coding for mRNA sequences which are antisense to transforming oncogenes, antineoplastic peptides such as tumor necrosis factor (TNF) and other cytokines, or transdominant negative mutants of transforming oncogenes can be delivered for expression at or near the tumor site.
  • genes coding for peptides known to display antiviral and/or antibacterial activity, or stimulate the host's immune system can also be administered.
  • genes encoding many of the various cytokines (or functional fragments thereof), such as the interleukins, interferons and colony stimulating factors will find use with the instant invention.
  • the gene sequences for a number of these substances are known.
  • antisense oligonucleotides capable of selectively binding to target sequences in host cells are provided herein for use in antisense therapeutics.
  • the nucleic acid is not linked or co-existing with other molecules or promoting materials that facilitate the uptake and integration of the genetic material into living cells.
  • promoting materials are selected from the group consisting of glycoprotein, lipoprotein, nucleoproteins and peptides, hormones, antibodies, growth factors, nucleic acid binding factors, proteinaceous cellular ligands, glycolipids, peptidoglycans, lectins, fatty acids, phospholipids, glycolipids, triglycerides, steroid hormones, cholesterol, single-stranded or double stranded DNA and intercalating agents.
  • composition of the invention may also include "release rate modifiers" which are pharmaceutically acceptable excipients, other than the biologically active agent and the controlled-release material, which modify the release of the biologically active agent from the microparticle.
  • release rate modifiers include but are not limited to zinc and various pharmaceutically acceptable surfactants.
  • composition of the invention may also include pharmaceutically acceptable excipients in addition to the rate controlling materials such as a binder, carrier, stabilizer, glidant, antioxidant, pH adjuster, buffer, anti-initant, and the like.
  • excipient generally refers to a substantially inert material that is nontoxic and does not interact with other components of the composition in a deleterious manner.
  • Suitable caniers that also act as stabilizers for peptides include pharmaceutical grades of dextrose, sucrose, lactose, trehalose, mannitol, sorbitol, inositol, dextran, and the like.
  • Other carriers include starch, cellulose, sodium or calcium phosphates, calcium sulfate, citric acid, tartaric acid, glycine, high molecular weight polyethylene glycols (PEG), and combinations thereof. It may also be useful to employ a charged lipid and/or detergent. Suitable charged lipids include, without limitation, phosphatidylcholines (lecithin), and the like.
  • Detergents will typically be a nonionic, anionic, cationic or amphoteric surfactant.
  • suitable surfactants include, for example, Tergitol® and Triton® surfactants (Union Carbide
  • polyoxyethylenesorbitans e.g., TWEEN® surfactants (Atlas Chemical Industries, Wilmington, DE)
  • polyoxyethylene ethers e.g. Brij
  • pharmaceutically acceptable fatty acid esters e.g., lauryl sulfate and salts thereof (SDS), and like materials.
  • the microparticles can comprise from about 1 to about 99 weight percent of the biologically active agent, for example from about 10 to about 80 weight percent of the biologically active agent.
  • the biologically active agent can therefore be present in amounts of from 2.0 to 70 weight percent such as from 25 to 60 weight percent or 25 to 50 weight percent. The actual amount depends on a number of factors include the nature of the biologically active agent, the dose desired and other variables readily appreciated by those skilled in the art.
  • Microparticles of the present invention can be designed to provide unique release characteristics.
  • the parameters which are varied to produce the characteristics include the polymer composition, polymer molecular weight, polyme ⁇ biologically active agent ratio, and microparticle diameter.
  • Heterogeneous compositions of uniquely designed microparticles are also encompassed in the present invention. Any permutation of the parameters designed to produce a desired release profile is within the scope of the invention. For example, all microparticles in the final formulation may be of approximately similar size but have different drug loadings (wt %). Alternatively, the same weight percent may be found in all of the microparticles but the sizes may differ. Further, heterogeneous populations of microparticles may include sub-populations formed with different polymer matrices, etc.
  • the material to be encapsulated (drugs or other active agents) is generally dispersed or emulsified, using stiners, agitators, or other dynamic mixing techniques, in a solvent containing a wall-forming material. Solvent is then removed from the microparticles, and thereafter the microparticle product is obtained.
  • the particles of the invention are provided as a free-flowing powder.
  • phase (A) containing the core material in solution or in suspension
  • aqueous phase (B) is canied out in the aqueous phase (B), again using conventional mixers, such as high-speed mixers, vibration mixers, or even spray nozzles, in which case the particle size of the microgranulates will be determined not only by the concentration of phase (A), but also by the emulsate or microparticulate size.
  • active agents biological or pharmaceutical agents
  • the microparticles form when the solvent containing an active agent and a polymer is emulsified or dispersed in an immiscible solution by stirring, agitating, vibrating, or some other dynamic mixing technique, often for a relatively long period of time.
  • U.S. Patent No. 4,389,330 describes the following method.
  • the desired agent is dissolved or dispersed in an appropriate solvent.
  • the agent-containing medium is added the polymeric matrix material in an amount relative to the active ingredient which gives a product of the desired loading of active agent.
  • all of the ingredients of the microparticle product can be blended in the solvent medium together.
  • Suitable solvents for the agent and the polymeric matrix material include organic solvents such as acetone, halogenated hydrocarbons such as chloroform, methylene chloride and the like, aromatic hydrocarbon compounds, halogenated aromatic hydrocarbon compounds, cyclic ethers, alcohols, ethyl acetate and the like.
  • Preferred solvents for the agent are methylene chloride or ethyl acetate.
  • the mixture of ingredients in the solvent can be emulsified in a continuous-phase processing medium; the continuous-phase medium being such that a dispersion of microdroplets containing the indicated ingredients is formed in the continuous -phase medium.
  • the continuous-phase processing medium and the organic solvent must be immiscible, and most commonly is water although nonaqueous media such as xylene and toluene and synthetic oils and natural oils can be used.
  • a surfactant is added to the continuous-phase processing medium to prevent the microparticles from agglomerating and to control the size of the solvent t ' • microdroplets in the emulsion.
  • a preferred surfactant-dispersing medium combination is a 1 to 10 wt. % poly (vinyl alcohol) in water mixture.
  • the dispersion is formed by mechanical agitation of the mixed materials.
  • An emulsion can also be formed by adding small drops of the active agent-wall forming material solution to the continuous phase processing medium.
  • the temperature during the formation of the emulsion is not especially critical but can influence the size and quality of the microparticles and the solubility of the drug in the continuous phase. Of course, it is desirable to have as little of the agent in the continuous phase as possible. Moreover, depending on the solvent and continuous -phase processing medium employed, the temperature must not be too low or the solvent and processing medium will solidify or the processing medium will become too viscous for practical purposes, or too high that the processing medium will evaporate, or that the liquid processing medium will not be maintained. Moreover, the temperature of the medium cannot be so high that the stability of the particular agent being incorporated in the microparticles is adversely affected.
  • the dispersion process can be conducted at any temperature which maintains stable operating conditions, which prefened temperature being about 30 °C to 60 °C, depending upon the drug and excipient selected.
  • the dispersion which is formed is a stable emulsion and from this dispersion the organic solvent immiscible fluid can optionally be partially removed in the first step of the solvent removal process.
  • the solvent can easily be removed by common techniques such as heating, the application of a reduced pressure or a combination of both.
  • the temperature employed to evaporate solvent from the microdroplets is not critical, but should not be that high that it degrades the agent employed in the preparation of a given microparticle, nor should it be so high as to evaporate solvent at such a rapid rate to cause defects in the wall forming material.
  • the solvent is removed in the first solvent removal step.
  • the dispersed microparticles in the solvent immiscible fluid medium are isolated from the fluid medium by any convenient means of separation.
  • the fluid can be decanted from the microparticle or the microparticle suspension can be filtered.
  • various combinations of separation techniques can be used if desired.
  • the remainder of the solvent in the microparticles is removed by extraction.
  • the microparticles can be suspended in the same continuous-phase processing medium used in step one, with or without surfactant, or in another liquid.
  • the extraction medium removes the solvent from the microparticles and yet does not dissolve the microparticles.
  • the extraction medium with dissolved solvent can optionally be removed and replaced with fresh extraction medium. This is best done on a continual basis.
  • the rate of extraction medium replenishment or a given process is a variable which can easily be determined at the time the process is performed and, therefore, no precise limits for the rate must be predetermined.
  • the microparticles are dried by exposure to air or by other conventional drying techniques such as vacuum drying, drying over a desiccant, or the like. This process is very efficient in encapsulating the agent since core loadings of up to 80 wt. %, preferably up to 60 wt.
  • controlled-release microparticles containing an active agent can be prepared through the use of static mixers as described in U.S. Patent No. 5,733,566, incorporated herein by reference in its entirety.
  • Static or motionless mixers consist of a conduit or tube in which is received a number of static mixing agents. Static mixers provide homogeneous mixing in a relatively short length of conduit, and in a relatively short period of time. With static mixers, the fluid moves through the mixer, rather than some part of the mixer, such as a blade, moving through the fluid.
  • a static mixer can be used to create an emulsion.
  • emulsion particle size including the density and viscosity of the various solutions or phases to be mixed, volume ratio of the phases, interfacial tension between the phases, static mixer parameters (conduit diameter; length of mixing element; number of mixing elements), and linear velocity through the static mixer.
  • Temperature is a variable because it effects density, viscosity, and interfacial tension.
  • the controlling variables are linear velocity, sheer rate, and pressure drop per unit length of static mixer.
  • an organic phase and an aqueous phase are combined.
  • the organic and aqueous phases are largely or substantially immiscible, with the aqueous phase constituting the continuous phase of the emulsion.
  • the organic phase includes an active agent as well as a wall-forming polymer or polymeric matrix material.
  • the organic phase can be prepared by dissolving an active agent in an organic or other suitable solvent, or by forming a dispersion or an emulsion containing the active agent.
  • the organic phase and the aqueous phase are pumped so that the two phases flow simultaneously through a static mixer, thereby forming an emulsion which comprises microparticles containing the active agent encapsulated in the polymeric matrix material.
  • the organic and aqueous phases are pumped through the static mixer into a large volume of quench liquid to extract or remove the organic solvent.
  • Organic solvent may be removed from the microparticles while they are washing or being stirred in the quench liquid. After the microparticles are washed in a quench liquid, they are isolated, as through a sieve, and dried.
  • An alternative process involves the use of a static mixer with co-solvents. This process outlined below, is also described in U.S. Patent No. 5,733,566 herein incorporated by reference.
  • a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons is used to dissolve both the agent and the polymer.
  • the solvent blend containing the dissolved agent and polymer is dispersed in an aqueous solution to form droplets.
  • the resulting emulsion is then added to an aqueous extraction medium preferably containing at least one of the solvents of the blend, whereby the rate of extraction of each solvent is controlled, whereupon the biodegradable microparticles containing the biologically active agent are formed.
  • the process has the advantages that less extraction medium is required because the solubility of one solvent in water is substantially independent of the other and solvent selection is increased, especially with solvents that are particularly difficult to extract. Accordingly, a number of conventional particle formation techniques can be carried out, for example spray drying, extrusion cutting and drying (spherunization), fluid bed coating of seed particles, coacervation, collection and drying, wet granulation and milling, milling of solids or larger particles, precipitation of amorphous solids, fluid bed granulation, evaporation or air drying followed by milling, spray or melt cooling or prilling, spray freeze-drying, compression (i.e., pelleting and grinding) and solution-loading of preformed matrix particles, (t'.e., sequential swelling and drying).
  • spray drying extrusion cutting and drying (spherunization)
  • fluid bed coating of seed particles coacervation, collection and drying
  • wet granulation and milling milling of solids or larger particles
  • precipitation of amorphous solids
  • the spray freeze-drying process is a viable process in terms of process efficiency (higher yields, nanower particle size distributions), and formulation flexibility.
  • the major disadvantage though is the potential porous morphology associated with the process due to the sublimation of the fine ice crystals leaving pores after freeze drying. It may hinder the efficiency for needleless syringe applications where dense particles might be required for skin penetration. Therefore, a formulation and/or a drying condition that can result in shrunk (or collapsed) particles is prefened.
  • excipients with Tg's (glass transition temperatures) lower than the primary drying temperature allow particles to collapse and result in dense particles.
  • hydrogel particles can be loaded with a guest substance, and the localized hydrogel environment manipulated to lower solubility characteristics of the guest, thereby forming a sustained release composition in accordance with the present invention.
  • Hydrogel compositions are well-known in the biomedical arts, and are commonly used as substrates for cell and tissue culture, impression materials for prosthetics, wound-packing materials, or as solid phase materials in size exclusion or affinity chromatography applications.
  • nonporous, deformed and/or derivatized agarose hydrogel compositions have been used in high- performance liquid chromatography and affinity chromatography methods (Li et al (1990) Preparative Biochem 20, 107-121), and superporous agarose hydrogel beads have been used as a support in hydrophobic interaction chromatography (Gustavsson et al (1999) J. Chromatography 830, 275-284).
  • hydrogel monomers Natural or synthetic
  • are commonly added to pharmaceutical compositions with an initiator and, sometimes, cross-linking agents
  • hydrogel particles for example, agarose or dextran particles
  • these hydrogel particles can be used as carrier systems for a wide variety of pharmacologically active guest agents, and are quite robust, making them uniquely well-suited for high-velocity particle injection delivery techniques. Since release of the guest agent from some such hydrogels will typically be dependent upon several factors, e.g.
  • a suitable hydrogel particle is loaded with a guest substance as described in International Application No. PCT/GB00/00349, and then excess amounts of a counter-ion, typically in the form of a salt, are added to the loaded particles to form an aggregate (e.g. divalent cations bind preferentially with histidine sites on a peptide or protein therapeutic agent, such as human growth hormone, to form a less soluble aggregate).
  • a counter-ion typically in the form of a salt
  • the counter-ions are used to associate with the guest substances, thereby lowering the available dissolution concentration of the guest as governed by the solubility of the guest/counter ion aggregate product from the hydrogel matrix.
  • a protein or peptide guest is loaded into a pre-formed hydrogel particle along with one or more suitable excipients, and the resulting loaded particles are dried.
  • a pharmaceutically acceptable salt solution e.g. sodium chloride
  • a pharmaceutically acceptable salt solution is then drawn into the loaded hydrogel particles to form aggregates with the protein guest, after which the particles are again dried.
  • water is absorbed by the hydrated hydrogel structure.
  • An abundance of the dissolving salt within the discrete environment of the hydrogel matrix holds the local concentration of the counter-ion near saturation, thereby lowering the solubility of the guest protein and slowing its release from the hydrogel particle to provide a sustained release delivery profile.
  • complexing agents can be added to such formulations to form less soluble metal/guest (e.g. protein) aggregates within the hydrogel carrier particle, whereby the lowered solubility of the complexed product creates a sustained release composition in accordance with the invention.
  • a zinc composition in the form of the chloride or acetate salt
  • the peptide is loaded into a suitable hydrogel particle using the methods of International Application No. PCT/GB00/00349.
  • the protein guest is added to the beads from a solution of about 10-200 mg/ml, together with stabilizing excipients such as trehalose or glycine, and the loaded hydrogel particles are then dried using a suitable drying technique such as lyophilisation.
  • a zinc acetate solution is prepared at near saturation and then adsorbed into the dry hydrogel particles in a second loading step.
  • the particles are then again dried, e.g. by lyophilisation.
  • Zinc-human growth human complexes will then occur upon dissolution of the guest protein during the second loading step, and/or upon rehydration of the particle upon delivery into an aqueous environment, e.g. a target tissue site.
  • the microparticle composition of this invention has particles of a size appropriate for high velocity delivery to an animal across th ⁇ stratum corneum or a transmucosal membrane.
  • the mean mass aerodynamic diameter (MMAD) of the particles is preferably larger than about 0.1 microns or about 10 microns, but smaller than about 100 microns, particularly less than 75 microns.
  • the majority of the particles will be in the range of about 20 to 75 microns.
  • a substantially homogenous population of particles of approximately the same size is provided.
  • less than 10% by weight of the particles may have a diameter which is 5 microns more or 5 microns less than the MMAD.
  • an optimal particle size is usually at least about 10 to 100 microns (larger than the size of a typical cell).
  • an optimal particle size is generally substantially smaller than 10 micron, e.g. 0.1 to 5 microns.
  • the average particle size of the powder can be measured as a mass mean aerodynamic diameter (MMAD) using conventional techniques such as microscopic techniques (where particles are sized directly and individually rather than grouped statistically), absorption of gasses, or permeability techniques.
  • MMAD mass mean aerodynamic diameter
  • automatic particle-size counters can be used (e.g., the Coulter Counter, HIAC Counter, or Gelman Automatic Particle Counter) to ascertain average particle size.
  • the particles can be assessed using the following methods.
  • Particle characterization for powder injection has different requirements than for traditional pharmaceutical products.
  • Most standard solid dosage forms place the highest value on facile dissolution.
  • density and particle size or morphology do not play an important role and individual particle density, an important parameter in determining momentum for powder injection, is typically not considered as long as flow characteristics are acceptable.
  • individual particle density is important and thus multiple methods of characterization are typically used. Absolute and theoretical density determinations are made and correlated with delivery, efficiency.
  • Envelope density information is particularly useful in characterizing the density of objects of inegular size and shape.
  • Envelope density, or “bulk density” is the mass of an object divided by its volume, where the volume includes that of its pores and small cavities.
  • Other, indirect methods are available which conelate to density of individual particles.
  • a number of methods of determining envelope density are known in the art, including wax immersion, mercury displacement, water absorption and apparent specific gravity techniques.
  • a number of suitable devices are also available for determining envelope density, for example, the GeoPycTM Model 1360, available from the Micromeritics Instrument Corp.
  • the difference between the absolute density and envelope density of a sample pharmaceutical composition provides information about the sample's percentage total porosity and specific pore volume.
  • Particle morphology particularly the aerodynamic shape of a particle
  • the particles can be readily assessed using standard light microscopy. It is prefened that the particles have a substantially spherical or at least substantially elliptical aerodynamic shape. It is also preferred that the particles have an axis ratio of 3 or less, i.e. from 3 : 1 to 1 :1, to avoid the presence of rod- or needle-shaped particles. These same microscopic techniques can also be used to assess the particle surface characteristics, e.g., the amount and extent of surface voids or degree of porosity.
  • particle size determination is well known to be significantly influenced by methodology (Etzler, F. M., Sa d ⁇ rson, M. S., Particle size analysis: a comparative study of various methods, Part. Part. Syst. Charact., 12,
  • the API Aerosizer® (Amherst Process Instruments, Hadley, MA) is a supersonic time of flight device in which the mode of measurement closely parallels
  • Quantitative techniques which are directly related to the powder injection process are measurement of particle size distribution pre vs post passage through a needleless syringe device and particle micro-hardness (i.e., impact strength when injected against a hard surface) (Ghadiri, M., Zhang, Z., Impact attrition of particulate solids, IFPRI Final Report, FRR 16-03 University of Surrey, UK, 1992).
  • Other techniques include direct particle indentation techniques (i.e., Nano Indenter II®, MTS Systems Corp, Oak Ridge, TN or Micro Hardness Tester®, Anton Paar GmbH, Graz, Austria) in which a probe is used to measure the effect of force against a single particle on a light microscope stage.
  • a "predetermined area” is intended to be a defined area of intact unbroken living skin or mucosal tissue. That area will usually be in the range of about 0.3 cm 2 to about 10 cm 2 . However, it will be appreciated by those skilled in the art of high velocity drug delivery that the area of skin or mucosal tissue through which drug is administered may vary significantly, depending on device configuration, dose, and the like.
  • One particular needleless syringe generally comprises an elongate tubular nozzle having a rupturable membrane initially closing the passage through the nozzle and ananged substantially adjacent to the upstream end of the nozzle.
  • Particles of a therapeutic agent to be delivered are disposed adjacent to the rupturable membrane and are delivered using an energizing means which applies a gaseous pressure to the upstream side of the membrane sufficient to burst the membrane and produce a supersonic gas flow (containing the pharmaceutical particles) through the nozzle for delivery from the downstream end thereof.
  • the particles can thus be delivered from the needleless syringe at delivery velocities of between Mach 1 and Mach 8 which are readily obtainable upon the bursting of the rupturable membrane.
  • needleless syringe devices useful in the process of this invention is found in the prior art. These devices are refened to as needleless syringe devices and are represented by a dermal PowderJect ® System and an oral PowderJect ® System. Needleless syringe devices for delivering particles are described in U.S. Patent No. 5,630,796 to Bellhouse et al, incorporated herein by reference. Although a number of specific device configurations are now available, such devices are typically provided as a pen-shaped instrum nt containing, in linear order moving from top to bottom, a gas cylinder, a particle cassette or package, and a supersonic nozzle with an associated silencer medium.
  • the microparticle composition or powder is sealed within a particle cassette, e.g., a container formed by two rupturable polymer membranes that are heat-sealed to a washer-shaped spacer to form a self-contained sealed unit.
  • the membrane material is selected to achieve a specific mode of opening and burst pressure that dictate the conditions at which the supersonic flow is initiated.
  • the device is actuated to release the compressed gas from the cylinder into an expansion chamber within the device.
  • the released gas contacts the particle cassette and, when sufficient pressure is built up, suddenly breaches the cassette membranes sweeping or entraining the particles into the supersonic nozzle for subsequent delivery.
  • the nozzle is designed to achieve a specific gas velocity and flow pattern to deliver a quantity of particles to a target surface of predefined area.
  • the silencer is used to attenuate the noise of the "sonic boom" produced by the membrane rupture.
  • a second needleless syringe device for delivering particles is described in commonly owned International Publication No. WO 96/20022.
  • This delivery system also uses the energy of a compressed gas source to accelerate and deliver powdered compositions; however, it is distinguished from the system of US Patent No. 5,630,796 in its use of a shock wave instead of gas flow to accelerate the particles. More particularly, an instantaneous pressure rise provided by a shock wave generated behind a flexible dome strikes the back of the dome, causing a sudden eversion of the flexible dome in the direction of a target surface.
  • This sudden eversion catapults a powdered composition (which is located on the outside of the dome) at a sufficient velocity, thus momentum, to penetrate target tissue, e.g., oral mucosal tissue.
  • the powdered composition is released at the point of full dome aversion.
  • the dome also serves to completely contain the high-pressure gas flow which therefore does not come into contact with the tissue. Because the gas is not released during this delivery operation, the system is inherently quiet. This design can be used in other enclosed or otherwise sensitive applications for example, to deliver particles to minimally invasive surgical sites.
  • Another needleless syringe configuration generally includes the same elements as described above, except that instead of having the pharmaceutical particles entrained within a supersonic gas flow, the downstream end of the nozzle is provided with a bistable diaphragm which is moveable between a resting "inverted" position (in which the diaphragm presents a concavity on the downstream face to contain the pharmaceutical particles) and an alternate "everted" position (in which the diaphragm is outwardly convex on the downstream face as a result of a supersonic Shockwave having been applied to the upstream face of the diaphragm).
  • the pharmaceutical particles contained within the concavity of the diaphragm are expelled at a high initial velocity from the device for transdermal delivery thereof to a targeted skin or mucosal surface.
  • prefened particle densities for use in needleless injection generally range between about 0.1 and 25 g/cm 3 , and more preferably between about 0.8 and 1.5 g/cm 3 .
  • the injection velocities preferably range between about 100 and 3,000 m/sec.
  • the individual particles In preparing powders according to the invention suitable for needleless delivery, it is important that the individual particles have a particular size range for optimal delivery, as discussed above. This size range preferably is about 10 microns to about 100 microns in effective diameter, preferably no more than 75 microns. It is also important that the individual particles have a structural integrity and density to survive the unique action of the gas jet with the delivery device and the ballistic impact with the skin or mucosal membrane at high velocities. It is further important that the vast majority of the particles making up a unit dosage powder for delivery are within the desired size range and stay within the size range during storage and delivery of the agent. It is further important that the pharmacologically-active agent is stable in the particle during storage and that the excipient- present in the particles allow the active agent to be released (by dissolution or diffusion) to act locally or to be transported systemically to the intended site of action.
  • Single unit dosages or multidose containers which are adapted for use in a needleless syringe and in which the particles of the invention may be packaged prior to use, can comprise a hermetically sealed container enclosing a suitable amount of the particles that make up a suitable dose.
  • the particle compositions can be packaged as a sterile formulation, and the hermetically sealed container can thus be designed to preserve sterility of the formulation until use in the methods of the invention.
  • the containers can be adapted for direct use in the above- referenced needleless syringe systems.
  • Powders of the present invention can thus be packaged in individual unit dosages for delivery via a needleless syrginge.
  • a "unit dosage” intends a dosage receptacle containing a therapeutically effective amount of a powder of the invention.
  • the dosage receptacle typically fits within a needleless syringe device to allow for transdermal delivery from the device.
  • Such receptacles can be capsules, foil pouches, sachets, cassettes or the like.
  • the container in which the particles are packaged can further be labeled to identify the composition and provide relevant dosage information.
  • the container can be labeled with a notice in the form prescribed by a governmental agency, for example the Food and Drug Administration, wherein the notice indicates approval by the agency under Federal law of the manufacture, use or sale of the hydrogel compositions contained therein for human administration.
  • a governmental agency for example the Food and Drug Administration
  • needleless syringes can be provided in a preloaded condition containing a suitable dosage of the hydrogel particles described herein.
  • the loaded syringe can be packaged in a hermetically sealed container, which may further be labeled as described above.
  • a number of test methods have been developed, or established test methods modified, in order to characterize performance of needleless syringe devices and the microparticle composition of this invention. These tests range from characterization of the powdered composition, assessment of the gas flow and particle acceleration, impact on artificial or biological targets, and measures of complete system performance.
  • PE peernetration energy
  • the film test-bed has been shown to be sensitive to particle delivery variations of all major device parameters including pressure, dose, particle size distribution and material, etc. and to be insensitive to the gas.
  • Aluminum of approximately 350 Angstrom thickness on a 125 ⁇ m polyester support is cunently used to test devices operated at up to 60 bar.
  • the metallized film test is extremely useful for device and formulation development purposes and also holds promise as a quality control tool. If all parameters except one are held constant it can be used as a relative measure to compare nozzles or drug cassette designs or formulations.
  • the test can give three types of information about system performance; total energy as well as spatial and temporal energy distribution.
  • One analysis mode generates a single measure of impact across the entire target area.
  • Alternative analysis give a spatially resolved indication of the homogeneity of delivery across the target. If used in a mode of electrical resistance measurement, the test can provide temporal information on particle impact.
  • mannitol standard as an excipient for drugs has been proven to deliver systemic concentrations in preclinical experiments, so the relative performance measure in the foam penetration test has a practical in vivo foundation.
  • Promising microparticle powders can be expected to show equivalent or better penetration to mannitol for anticipation of adequate performance in preclinical or clinical studies. This simple, rapid test has value as a relative method of evaluation of powders and is not intended to be considered in isolation.
  • a further indicator of particle performance is to test the ability of various candidate compositions to withstand the forces associated with high-velocity particle injection techniques, that is, the forces from contacting particles at rest with a sudden, high velocity gas flow, the forces resulting from particle-to-particle impact as the powder travels through the needleless syringe, and the forces resulting from particle-to-device collisions also as the powder travels through the device.
  • a simple particle attrition test has been devised which measures the change in particle size distribution between the initial composition, and the composition after having been delivered from a needleless syringe device.
  • the test is conducted by loading a particle composition into a needleless syringe as described above, and then discharging the device into a flask containing a carrier fluid in which the particular composition is not soluble (e.g., mineral oil, silicone oil, etc.).
  • a carrier fluid in which the particular composition is not soluble (e.g., mineral oil, silicone oil, etc.).
  • the carrier fluid is then collected, and particle size distribution in both the initial composition and the discharged composition is calculated using a suitable particle sizing apparatus, e.g., an AccuSizer® model 780 Optical Particle Sizer.
  • Compositions that demonstrate less than about 50%, more preferably less than about 25% or less than about 20%, reduction in mass mean diameter (as determined by the AccuSizer apparatus) after device actuation are deemed suitable for use in the needleless syringe systems described herein.
  • microparticles or model particles are injected into dermatomed, full thickness human abdomen skin samples.
  • Replicate skin samples after injection can be placed on modified Franz diffusion cells containing 32°C water, physiologic saline or buffer.
  • Additives such as surfactants may be used to prevent binding to diffusion cell components.
  • Two kinds of measurements can be made to assess either physical attributes of the delivery or performance of the formulation in the skin.
  • To measure physical effects, i.e. the effect of powder injection on the barrier function of skin, the transepidermal water loss (TEWL) can be measured.
  • a preparation of cross-linked, sulfated dextran affinity chromatography resin beads were obtained from a commercial source (Sigma. St. Louis, MO). More particularly, 4% cross-linked suflated beaded dextran was obtained as a lyophilized powder stabilized in lactose. The sulfate ligand will bind with a charged guest substance (e.g. a peptide or protein) at low salt concentration. This binding is reversible and the bound guest can be desorbed at a high salt concentration.
  • lysozyme (Sigma) was loaded into the beads using the techniques described in commonly held International Application No. PCT/GB00/00349.
  • each gram of the sulfated dextran beads was washed with approximately 3 x 500 ml deionized water. Excess water was removed by vacuum filtration.
  • a loading solution was prepared by dissolving 4.00g lysozyme in 200 ml deionized water, yielding a 20 mg/ml solution. The loading solution was added to the hydrated dextran beads at a 1 : 1 ratio to provide a suspension. The suspension was stirred for one hour, and excess solution was drained from the hydrated beads. The loaded beads were then divided into two portions.
  • the first portion (5.7cc, experimental) was placed into a column (Econo column, BioRad, Hercules, CA) and washed with a phosphate buffered saline (PBS) solution (pH 7.4) for 19.6 hours, then eluted with 21.2 ml of a high salt elution buffer (1.0M ammonium sulfate, 50 mM sodium phosphate, pH 7.2).
  • the second portion (4.7cc, control) was loaded into a similar column and immediately eluted with the elution buffer alone. The amount of lysozyme released from the dextran beads during the PBS wash was determined by comparison against the amount of lysozyme eluted by the elution solution for both the experimental and the control portions.
  • Lysozyme concentration was determined using a UV detector (BioRad UV detector).
  • a standard curve UV absorption vs lysozyme concentration was prepared by measuring the UV absorption of stock lysozyme solutions at different concentration ranging from 1 mg/ml to 4 mg/ml. Concentrations of the unknowns were then determined by extrapolation of the standard curve. The amount of lysozyme released during the PBS wash of the experimental portion was not detectable with the UV detector. However, the amount of lysozyme eluted in the elution buffer for the experimental (PBS washed beads) and the control portions were 3.72 mg/ml beads and 10.5 mg/ml wet beads, respectively. This indicates that the average sustained release rate of the lysozyme from the hydrogel particles over the
  • Lysozyme concentration was determined using a UV detector (BioRad UV detector).
  • a standard curve UV absorption vs lysozyme concentration was prepared by measuring the UV absorption of stock lysozyme solutions at different concentration ranging from 1 mg ml to 4 mg/ml. Concentrations of the unknowns were then determined by extrapolation of the standard curve. The amount of lysozyme released during the PBS wash of the experimental portion was not detectable with the UV detector. However, the amount of lysozyme eluted in the elution buffer for the experimental (PBS washed beads) and the control portions were 3.72 mg/ml beads and 10.5 mg/ml wet beads, respectively. This indicates that the average sustained release rate of the lysozyme from the hydrogel particles over the 19.6 hour period was 0.3 mg/hr/g wet bead, or 3.2% per hour, where release was substantially linear with time.
  • Example 2 The sustained release study described above in Example 1 was repeated except, in this instance, a different elution rate was used to determine if the rate of release of the lysozyme guest substance from the dextran is a function of the flow rate of the elution buffer.
  • sulfated dextran beads were loaded with lysozyme as described above in Example 1.
  • the specifics of the loaded were as follows: 42.4g of the hydrated dextran beads were stirred in 100ml of lysozyme solution (20.11 mg.ml) for 1 hour. The loaded beads were then loaded into a column as above for the sustained release study.
  • the PBS wash (pH 7.4) was used to elute lysozyme from the beads at a flow rate of 0.84 ml/min for 20.6 hours.
  • the eluted solution was collected in fractions, and the elution fractions were analyzed with HPLC for lysozyme concentration using a Vydac CIS HPLC column.
  • the remaining lysozyme in the beads were then eluted with the salt elution buffer at a rate of 0.84 ml/min.
  • the amount of lysozyme protein that eluted with the PBS wash was 39.51 mg and, from the high salt elution, 40.34 mg.
  • Accumulated percent lysozyme release (Y) was plotted against elution time (X).

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne une composition à administrer à un sujet à l'aide d'une seringue sans aiguille renfermant des particules dont le diamètre aérodynamique massique moyen oscille entre 1 et 250 microns et dont la densité de l'enveloppe oscille entre 0,1 et 25 g/cm3, les particules comprenant un agent biologiquement actif et une substance à libération lente régulant la libération de l'agent actif.
PCT/GB2000/000847 1999-03-08 2000-03-08 Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs Ceased WO2000053160A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU29312/00A AU770235B2 (en) 1999-03-08 2000-03-08 Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
CA002364198A CA2364198A1 (fr) 1999-03-08 2000-03-08 Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs
NZ513981A NZ513981A (en) 1999-03-08 2000-03-08 Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
JP2000603649A JP2002538195A (ja) 1999-03-08 2000-03-08 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
EP00907848A EP1158961A1 (fr) 1999-03-08 2000-03-08 Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26442799A 1999-03-08 1999-03-08
US12326499P 1999-03-08 1999-03-08
US60/123,264 1999-03-08
US09/264,427 1999-03-08

Publications (1)

Publication Number Publication Date
WO2000053160A1 true WO2000053160A1 (fr) 2000-09-14

Family

ID=26821383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000847 Ceased WO2000053160A1 (fr) 1999-03-08 2000-03-08 Administration de formulations microparticulaires a l'aide d'une seringue sans aiguille pour la liberation lente de composes bioactifs

Country Status (6)

Country Link
EP (1) EP1158961A1 (fr)
JP (1) JP2002538195A (fr)
AU (1) AU770235B2 (fr)
CA (1) CA2364198A1 (fr)
NZ (1) NZ513981A (fr)
WO (1) WO2000053160A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064117A1 (fr) * 2001-02-14 2002-08-22 Prometic Biosciences Ltd. Composition sterile et preparation de cette composition
WO2002100380A1 (fr) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Production de particules dures, denses
US6558348B2 (en) 2000-04-07 2003-05-06 Equidyne Systems, Inc. Low cost disposable needleless injector system for variable and fixed dose applications
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
US7666844B2 (en) 1999-04-16 2010-02-23 Novo Nordisk A/S Dry mouldable drug formulation
WO2010059836A1 (fr) 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
WO2010084499A2 (fr) 2009-01-26 2010-07-29 Israel Institute For Biological Research Composés spiro hétérocycliques bicycliques
EP2476680A1 (fr) 2008-01-11 2012-07-18 Albany Molecular Research, Inc. Pyridoindoles à substitution (1-azinone)
US20130101609A1 (en) * 2010-01-24 2013-04-25 Novartis Ag Irradiated biodegradable polymer microparticles
EP2628727A2 (fr) 2007-11-21 2013-08-21 Decode Genetics EHF Inhibiteurs de PDE4 biaryle pour le traitement de troubles pulmonaires et cardiovasculaires

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5630796A (en) * 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
WO1997048485A1 (fr) * 1996-06-17 1997-12-24 Powderject Research Limited Procede d'obtention de compositions en particules denses pour administration par voie transdermique
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO2000013668A1 (fr) * 1998-09-03 2000-03-16 Quadrant Healthcare (Uk) Limited Microparticules
WO2000019982A1 (fr) * 1998-10-01 2000-04-13 Powderject Research Limited Microparticules a revetement applique par pulverisation utilisees dans une seringue sans aiguille

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
JP4619457B2 (ja) * 1993-11-18 2011-01-26 シルテックス、メディカル、リミテッド 徐放性製剤
US5898271A (en) * 1996-04-25 1999-04-27 U.S. Philips Corporation Hollow cathodes with an I-beam or C-beam cross section for a plasma display device
ES2195317T3 (es) * 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
CN1230152C (zh) * 1999-02-03 2005-12-07 鲍德杰克特研究有限公司 水凝胶颗粒制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5630796A (en) * 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
WO1997048485A1 (fr) * 1996-06-17 1997-12-24 Powderject Research Limited Procede d'obtention de compositions en particules denses pour administration par voie transdermique
WO2000013668A1 (fr) * 1998-09-03 2000-03-16 Quadrant Healthcare (Uk) Limited Microparticules
WO2000019982A1 (fr) * 1998-10-01 2000-04-13 Powderject Research Limited Microparticules a revetement applique par pulverisation utilisees dans une seringue sans aiguille

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEHTA R C ET AL: "Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 41, no. 3, 1 September 1996 (1996-09-01), pages 249 - 257, XP004037590, ISSN: 0168-3659 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666844B2 (en) 1999-04-16 2010-02-23 Novo Nordisk A/S Dry mouldable drug formulation
US8084053B2 (en) 1999-04-16 2011-12-27 Novo Nordisk A/S Dry mouldable drug formulation
US6558348B2 (en) 2000-04-07 2003-05-06 Equidyne Systems, Inc. Low cost disposable needleless injector system for variable and fixed dose applications
US6913592B2 (en) 2000-04-07 2005-07-05 Hns International, Inc. Low cost disposable needleless injector system for variable and fixed dose applications
WO2002064117A1 (fr) * 2001-02-14 2002-08-22 Prometic Biosciences Ltd. Composition sterile et preparation de cette composition
WO2002100380A1 (fr) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Production de particules dures, denses
EP2088154A1 (fr) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles gastro-intestinaux
EP2674417A2 (fr) 2007-11-21 2013-12-18 Decode Genetics EHF Inhibiteurs de PDE4 biaryle pour le traitement de l'inflammation
EP2628727A2 (fr) 2007-11-21 2013-08-21 Decode Genetics EHF Inhibiteurs de PDE4 biaryle pour le traitement de troubles pulmonaires et cardiovasculaires
EP2476680A1 (fr) 2008-01-11 2012-07-18 Albany Molecular Research, Inc. Pyridoindoles à substitution (1-azinone)
WO2010059836A1 (fr) 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
WO2010084499A2 (fr) 2009-01-26 2010-07-29 Israel Institute For Biological Research Composés spiro hétérocycliques bicycliques
US20130101609A1 (en) * 2010-01-24 2013-04-25 Novartis Ag Irradiated biodegradable polymer microparticles

Also Published As

Publication number Publication date
AU770235B2 (en) 2004-02-19
NZ513981A (en) 2004-02-27
JP2002538195A (ja) 2002-11-12
AU2931200A (en) 2000-09-28
CA2364198A1 (fr) 2000-09-14
EP1158961A1 (fr) 2001-12-05

Similar Documents

Publication Publication Date Title
US20100173005A1 (en) Microparticle formulations for sustained-release of bioactive compounds
AU780397B2 (en) Hydrogel particle formulations
US7229645B2 (en) Spray freeze-dried compositions
CA2342206C (fr) Microparticules
US20020150626A1 (en) Lipid-protein-sugar particles for delivery of nucleic acids
NZ552576A (en) Salt adjuvant-containing gel-forming free flowing compositions in a powder form for transdermal delivery from a needless syringe
CN101687094A (zh) 含有药物颗粒和/或药物吸附颗粒的固体溶液穿孔器
AU770235B2 (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
JP2002526400A (ja) 無針シリンジにおける使用のためのスプレー被覆した微小粒子
US20020051821A1 (en) Aliginate particle formulation
US20050191361A1 (en) Hydrogel particle formation
US20040213798A1 (en) Spray-dried alum compositions
Comolli et al. Polymeric microparticles
Das et al. Development of Biodegradable Polymeric Nanoparticles for Systemic Delivery
Patel et al. A REVIEW ON MICROSPHERES AS CONTROLLED DRUG DELIVERY CARRIER.
as Promising Biolological Medicinal Chemistry
AU2001275371A1 (en) Powder compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 513981

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2364198

Country of ref document: CA

Ref country code: CA

Ref document number: 2364198

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 603649

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 29312/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000907848

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000907848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 29312/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000907848

Country of ref document: EP